Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation Survey

News provided by

May 14, 2024, 07:00 ET

Servier is ranked 1st for patient centricity, information sharing, integrity, services 'beyond the pill', engagement and communication and overall familiarity in the industry

BOSTON, May 14, 2024 /PRNewswire/ -- Servier, a leader in oncology committed to delivering transformative therapies to patients, is No. 1 in six categories, among 37 companies featured in PatientView's 2023-2024 Corporate Reputation of Pharma survey. This annual survey includes feedback from more than 300 patient organizations on their perceptions, experiences and familiarity with pharmaceutical companies.

"Patients are the North Star for everything we do at Servier. Their experiences, stories, and insights guide our work and make us better at what we do," said David K. Lee, CEO of Servier Pharmaceuticals. "Our Patient Office, who stays in lockstep with our patients and the groups that serve them, and our unique governance model, allows us to be truly patient centric across all corners of the organization. This year's PatientView survey results reaffirm our continued commitment to putting patients first and the critical role they play in every aspect of our work, from drug development to education, outreach, and access."

In the report, patient groups ranked Servier 1st for patient centricity, information sharing, integrity, services 'beyond the pill', engagement and communication and overall familiarity in the industry.

"Understanding the increasing complexities and challenges advocacy groups, patients and caregivers face enables us to meet them where they are and provide needed tools and resources every step of the way," said Wendy Poage, VP of Servier's Patient Office. "Having the trust of patient groups fuels our passion to be the best partner for them, our patients and caregivers."

For more information on Servier Pharmaceuticals patient support services, please visit servier.us/patient-support and https://www.servierone.com/.

About the Corporate Reputation of Pharma – from the Perspective of U.S.-Based Patient Groups

2023's 314 respondent U.S. patient groups specialized in a wide range of therapy areas—the largest representation (113 respondent patient groups) being cancer patient groups. The 314 stated that, collectively, they had actively supported and served some 12 million US patients during 2023/24. The PatientView annual Corporate Reputation of Pharma survey gives patient-advocacy groups an opportunity to comment on, and assess, the pharma industry's performance. Companies are ranked against their peers. The survey results reinforce the dedication, commitment and hard work companies invest internally to ensure engagement with patients and advocacy groups is reflective of the patients they serve.

About Servier Pharmaceuticals

Servier Pharmaceuticals LLC is a commercial-stage company with a passion for innovation and improving the lives of patients, their families and caregivers. As a privately held company, Servier has the unique freedom to devote all of its time and energy towards patients who require our treatments, care and innovation in areas of unmet medical need.

As a leader in oncology, Servier is committed to finding solutions that will address today's challenges. The company's oncology portfolio includes innovative medicines designed to bring more life-saving treatments to a greater number of patients, across the entire spectrum of disease and in a variety of tumor types. Servier has significantly accelerated its investment in hard-to-treat cancers with more than 50% of its research and development dedicated to delivering significant advances in areas of high unmet need that may truly move the needle for our patients.

Servier believes co-creation is fundamental to driving innovation and is actively building alliances, acquisitions, licensing deals and partnerships that bring solutions and accelerate access to therapies. With the company's commercial expertise, global reach, scientific expertise and commitment to clinical excellence, Servier Pharmaceuticals is dedicated to bringing the promise of tomorrow to the patients that we serve.

For more information: www.servier.us.

Press Contact:
Servier Pharmaceuticals (U.S.)
Erin Smith
[email protected]

Disclosures

This release contains general information about the Servier Group and its entities (hereinafter "Servier and its Affiliates") and is intended for informational purposes only. The information is thought to be reliable; however, Servier and its Affiliates make no representation as to the accuracy or completeness of the information contained herein or otherwise provided and accept no responsibility or liability, in contract, in tort, in negligence, or otherwise, should the information be found to be inaccurate or incomplete in any respect.

Servier and its Affiliates are not acting as an advisor to the recipient of this information, and the ultimate decision to proceed with any transaction rests solely with the recipient of this information. Therefore, prior to entering into any proposed transaction, the recipient of this information should determine, without reliance upon Servier or its Affiliates, the economic risks and merits, as well as the legal, tax, and accounting characterizations and consequences, of the transaction and that it is able to assume these risks.

This statement also contains forward-looking statements that are subject to varying levels of uncertainty and risk. Investigational new drugs and indications are subject to further scientific and medical review and regulatory approval. They are not approved for use by the FDA.

Any reliance placed on this document is done entirely at the risk of the person placing such reliance. The information contained in this document is neither an offer to sell nor the solicitation of an offer to enter into a transaction.

The content of this document is a summary only, is not complete, and does not include all material information about Servier and its Affiliates, including potential conflicts of interest.

To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates disclaim all representations, warranties, conditions and guarantees, whether express, implied, statutory or of other kind, nor does it accept any duty to any person, in connection with this document. Without prejudice to the generality of the foregoing, Servier and its Affiliates do not warrant or represent that the information or opinions contained in this document is accurate or complete.

To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates shall not be liable for any loss, damage or expense whatsoever, whether direct or indirect, howsoever arising, whether in contract, tort (including negligence), strict liability or otherwise, for direct, indirect, incidental, consequential, punitive or special damages arising out of or in connection with this document, including (without limitation) any course of action taken on the basis of the same. The estimates, strategies, and views expressed in this document are based upon past or current data and information and are subject to change without notice.

SOURCE Servier Pharmaceuticals